• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

固定复方药物疗法。

Fixed combination drug therapy.

作者信息

Shenfield G M

出版信息

Drugs. 1982 Jun;23(6):462-80. doi: 10.2165/00003495-198223060-00003.

DOI:10.2165/00003495-198223060-00003
PMID:7049658
Abstract

Almost half of all marketed drugs are fixed combination preparations, yet the World Health Organization included only 7 in its list of 240 "essential' drugs. There has been little scientific study of these preparations but much emotion and rhetoric has been expended both for and against them. Potential advantages of fixed combination preparations include: increased compliance, synergy and increased efficacy, and reduced side effects and cost. Potential disadvantages include: inflexible fixed dose ratio, incompatible pharmacokinetics, increased toxicity, and physician and pharmacist ignorance of content. There are a few combinations of undisputed value such as oral contraceptives, levodopa with decarboxylase inhibitors, and pyrimethamine with sulphadoxine. In other cases fixed-dose combinations may have value in strictly specified circumstances, but are probably overprescribed. There is also widespread, unjustified use of combinations in over-the-counter preparations which may have unrecognised adverse effects. Combinations should only be used if each component is necessary for the desired effect and if the advantages outweigh the added risks of using 2 or more drugs. Before prescribing combination drugs, clinicians should always ask themselves a series of questions of which the most important is whether the patient needs each drug in a particular combination, or if 1 component alone would be adequate. In general, government regulatory bodies in "developed' countries are attempting to curb the use of combination drugs, but a more profitable approach might be to better educate doctors on both the advantages and disadvantages of fixed combination preparations leading to improved prescribing habits.

摘要

几乎一半的市售药品都是复方制剂,但世界卫生组织在其240种“基本”药物清单中仅列入了7种。对这些制剂的科学研究很少,但人们对它们的支持和反对却投入了大量的情感和言辞。复方制剂的潜在优势包括:提高依从性、协同作用和提高疗效,以及减少副作用和成本。潜在的缺点包括:固定剂量比例缺乏灵活性、药代动力学不相容、毒性增加,以及医生和药剂师对其成分的忽视。有一些具有无可争议价值的组合,如口服避孕药、左旋多巴与脱羧酶抑制剂,以及乙胺嘧啶与周效磺胺。在其他情况下,固定剂量组合在严格规定的情况下可能有价值,但可能存在处方过度的情况。在非处方制剂中也广泛存在不合理使用组合的情况,这可能会产生未被认识到的不良反应。只有当每种成分对预期效果都是必要的,并且其优势超过使用两种或更多药物所增加的风险时,才应使用组合制剂。在开具复方药物之前,临床医生应始终问自己一系列问题,其中最重要的是患者是否需要特定组合中的每种药物,或者仅一种成分是否就足够了。一般来说,“发达国家”的政府监管机构正在试图遏制复方药物的使用,但一种更有益的方法可能是更好地教育医生了解固定复方制剂的优缺点,从而改善处方习惯。

相似文献

1
Fixed combination drug therapy.固定复方药物疗法。
Drugs. 1982 Jun;23(6):462-80. doi: 10.2165/00003495-198223060-00003.
2
Report of a workshop on fixed-ratio drug combinations.固定剂量复方药物研讨会报告
Eur J Clin Pharmacol. 1975 Feb 28;8(2):149-54. doi: 10.1007/BF00561565.
3
Fixed-dose combination therapy with statins: strengths, limitations, and clinical and regulatory considerations.他汀类药物的固定剂量联合疗法:优势、局限性以及临床和监管方面的考量
Am J Cardiovasc Drugs. 2008;8(3):155-60. doi: 10.2165/00129784-200808030-00002.
4
Using fixed-dose combination therapies to achieve blood pressure goals.使用固定剂量联合疗法来实现血压目标。
Clin Drug Investig. 2008;28(11):713-34. doi: 10.2165/00044011-200828110-00005.
5
Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.固定剂量复方制剂治疗高血压的理论依据:循环往复。
Drugs. 2002;62(3):443-62. doi: 10.2165/00003495-200262030-00003.
6
Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same?固定剂量复方抗高血压药物与靶器官损害的减少:它们都一样吗?
Am J Cardiovasc Drugs. 2007;7(6):413-22. doi: 10.2165/00129784-200707060-00004.
7
[For an optimal use of fixed drug combinations].
Therapie. 2017 Dec;72(6):665-668. doi: 10.1016/j.therap.2017.07.003. Epub 2017 Aug 3.
8
The danger of fixed drug combinations.固定剂量复方制剂的风险
Int J Clin Pharmacol Biopharm. 1975 Jul;12(1-2):70-3.
9
The assessment of risks, benefits and availability of non-narcotic analgesics. A commonsense approach.非麻醉性镇痛药的风险、益处及可获得性评估:一种基于常识的方法。
Med Toxicol. 1986;1 Suppl 1:115-20.
10
A conservative method of testing whether combination analgesics produce additive or synergistic effects using evidence from acute pain and migraine.采用急性疼痛和偏头痛的证据,保守地测试联合镇痛药是否产生相加或协同作用的方法。
Eur J Pain. 2012 Apr;16(4):585-91. doi: 10.1016/j.ejpain.2011.08.009.

引用本文的文献

1
An eco-friendly bioanalytical RP-HPLC method coupled with fluorescence detection for simultaneous estimation of felodipine and metoprolol.一种结合荧光检测的环保型生物分析反相高效液相色谱法,用于同时测定非洛地平和美托洛尔。
BMC Chem. 2025 May 23;19(1):141. doi: 10.1186/s13065-025-01507-0.
2
Localized Cancer Treatment Using Thiol-Ene Hydrogels for Dual Drug Delivery.使用硫醇-烯水凝胶进行双药递送的局部癌症治疗
Biomacromolecules. 2025 May 12;26(5):3234-3254. doi: 10.1021/acs.biomac.5c00387. Epub 2025 Apr 8.
3
The Anticancer Activity of Monosaccharides: Perspectives and Outlooks.

本文引用的文献

1
Prescribing and the british national formulary.处方与《英国国家处方集》
Br Med J. 1966 Sep 10;2(5514):635-7. doi: 10.1136/bmj.2.5514.635.
2
ISONIAZID-INDUCED ENCEPHALOPATHY.异烟肼所致脑病
Lancet. 1965 Aug 28;2(7409):440. doi: 10.1016/s0140-6736(65)90789-0.
3
ERRORS OF COMPLEX PRESCRIBING.
Lancet. 1965 Feb 13;1(7381):370-3. doi: 10.1016/s0140-6736(65)91799-x.
单糖的抗癌活性:前景与展望
Cancers (Basel). 2024 Aug 6;16(16):2775. doi: 10.3390/cancers16162775.
4
Efficacy of Microneedling and CO2 Laser for Acne Scar Remodelling: A Comprehensive Review.微针疗法与二氧化碳激光用于痤疮瘢痕重塑的疗效:一项综述
Cureus. 2024 Feb 27;16(2):e55092. doi: 10.7759/cureus.55092. eCollection 2024 Feb.
5
Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer.重新利用蛋白酶体抑制剂以改善三阴性乳腺癌的治疗
Cell Death Discov. 2024 Jan 29;10(1):57. doi: 10.1038/s41420-024-01819-5.
6
Advances in drug delivery systems, challenges and future directions.药物递送系统的进展、挑战与未来方向。
Heliyon. 2023 Jun 24;9(6):e17488. doi: 10.1016/j.heliyon.2023.e17488. eCollection 2023 Jun.
7
Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment.含溴结构域及额外末端结构域抑制剂BMS-986158通过增加CDK9磷酸化和募集在体外和体内逆转潜伏性HIV-1感染。
Pharmaceuticals (Basel). 2022 Mar 10;15(3):338. doi: 10.3390/ph15030338.
8
Multidrug resistance crisis during COVID-19 pandemic: Role of anti-microbial peptides as next-generation therapeutics.新冠疫情期间的多药耐药危机:抗菌肽作为下一代治疗药物的作用。
Colloids Surf B Biointerfaces. 2022 Mar;211:112303. doi: 10.1016/j.colsurfb.2021.112303. Epub 2021 Dec 20.
9
Novel Curcumin-Resveratrol Solid Nanoparticles Synergistically Inhibit Proliferation of Melanoma Cells.新型姜黄素-白藜芦醇固体纳米颗粒协同抑制黑色素瘤细胞增殖。
Pharm Res. 2021 May;38(5):851-871. doi: 10.1007/s11095-021-03043-7. Epub 2021 May 12.
10
Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review.与单一制剂相比,复方制剂是否能提高患者的依从性?一项系统评价。
Pharmaceutics. 2020 Feb 22;12(2):190. doi: 10.3390/pharmaceutics12020190.
4
Outpatient bronchodilator therapy.门诊支气管扩张剂治疗
Lancet. 1957 May 11;272(6976):956-60. doi: 10.1016/s0140-6736(57)91282-5.
5
Effect of restrictions on prescribing patterns for dextropropoxyphene.对右丙氧芬处方模式限制的影响。
Br Med J. 1980 Sep 6;281(6241):651-3. doi: 10.1136/bmj.281.6241.651.
6
When are drug combinations justified?何时药物联合使用是合理的?
Drug Ther Bull. 1980 May 9;18(10):37-40.
7
Action from the CRM: barbiturates.CRM的作用:巴比妥类药物。
Drug Ther Bull. 1980 Feb 1;18(3):9-11.
8
Trimethoprim resistance in Finland after five years' use of plain trimethoprim.在单纯使用甲氧苄啶五年后芬兰出现的甲氧苄啶耐药性。
Br Med J. 1980 Jan 12;280(6207):72-4. doi: 10.1136/bmj.280.6207.72.
9
Drug utilization - theory and practice. The present situation in the Federal Republic of Germany.
Eur J Clin Pharmacol. 1981;19(6):387-94. doi: 10.1007/BF00548580.
10
Theophylline-salbutamol interaction: bronchodilator response to salbutamol at maximally effective plasma theophylline concentrations.茶碱-沙丁胺醇相互作用:在最大有效血浆茶碱浓度下对沙丁胺醇的支气管扩张反应。
Br J Clin Pharmacol. 1981 Feb;11(2):203-8. doi: 10.1111/j.1365-2125.1981.tb01125.x.